Antiemetics Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

Antiemetics Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

Antiemetics Drugs Market By Drug Type (Serotonin-Receptor Antagonists, Antihistamines, Anticholinergics, Dopamine Receptor Antagonists, Neurokinin Receptor Antagonists, And Others), Distribution Channel (Hospitals & Clinics, Retail Pharmacy, And Others) And Geography (North America, Europe, Asia-Pacific, And Rest Of The World) is expected to grow at a steady CAGR forecast till 2030 owing to the growing prevalence of cancer and gastroenteritis globally and expanding use in various condition

The global antiemetics drugs market is estimated to grow at a CAGR of 6.31% during the forecast period from 2024 to 2030. The demand for antiemetic drugs, which are medications used to prevent or alleviate nausea and vomiting, is on the rise due to several factors. One significant reason is the increasing prevalence of conditions and treatments that induce nausea and vomiting, such as chemotherapy, radiation therapy, gastroenteritis, gastroparesis, irritable bowel syndrome, and certain surgical procedures. Additionally, there is a growing awareness among healthcare professionals and patients about the importance of managing these symptoms effectively to improve quality of life during illness or recovery. Moreover, with advancements in medical technology and pharmaceutical research, new antiemetic drugs with improved efficacy and fewer side effects are continuously being developed, expanding the options available to patients and healthcare providers. As a result, the demand for antiemetics is expected to continue to increase during the forecast period from 2024 to 2030, as the population ages and as the prevalence of conditions requiring nausea and vomiting management persists.

Antiemetics Drugs Market Dynamics:

The International Agency for Research on Cancer (IARC) reported in 2022 that nearly 20 million new cancer cases and close to 10 million deaths from cancer occurred worldwide that year. Based on demographic trends, it's predicted that the annual number of new cancer cases will rise to 35 million by 2050, marking a significant 77% increase from 2022. This surge in cancer diagnoses is expected to drive the demand for antiemetic drugs, particularly for managing chemotherapy-induced nausea and vomiting, leading to positive growth in the antiemetics drugs market.

Moreover, data published by the National Library of Medicine in 2023 highlights acute gastroenteritis as a prevalent cause of emergency department visits and hospitalizations, especially in children. Globally, acute gastroenteritis contributes to an estimated 89.5 million disabilities and 1.45 million deaths annually. Given its frequency and potential severity, acute gastroenteritis poses substantial burdens on both populations and healthcare systems. Antiemetic drugs, designed specifically to alleviate nausea and vomiting, are integral to managing gastroenteritis. They not only relieve symptoms but also facilitate hydration, promote oral intake, and enhance patient comfort and well-being during the illness.

In light of these factors, the demand for antiemetic drugs is poised to increase significantly. Their pivotal role in managing both chemotherapy-induced nausea and vomiting in cancer patients and symptoms of gastroenteritis underscores their importance, driving overall growth in the antiemetics drugs market..

However, the various safety risks and adverse effects associated with antiemetics drugs, and the pricing challenges associated with generic competition, may act as factors that are expected to limit the growth of the antiemetics drugs market.

Antiemetics Drugs Market Segment Analysis:

Antiemetics Drugs Market by Drug Type (Serotonin-Receptor Antagonists, Antihistamines, Anticholinergics, Dopamine Receptor Antagonists, Neurokinin Receptor Antagonists, and Others), Distribution Channel (Hospitals & Clinics, Retail Pharmacy, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the drug type segment of the antiemetics drugs market, serotonin-receptor antagonists are estimated to amass a significant revenue share in the antiemetics drugs market in 2023. The serotonin-receptor antagonists include drugs like Ondansetron, Dolasetron, and others. Serotonin receptor antagonists are highly effective in preventing and controlling nausea and vomiting, particularly chemotherapy-induced nausea and vomiting. They block serotonin receptors in the gastrointestinal tract and central nervous system, thereby reducing the signals that trigger nausea and vomiting.

Moreover, these antagonists are effective against a wide range of emetogenic stimuli, including chemotherapy, radiation therapy, and postoperative nausea and vomiting. This broad spectrum of action makes them versatile agents for managing various types of nausea and vomiting. On the other hand, Serotonin receptor antagonists have been available on the market for several decades and have established a strong market presence. They are familiar to healthcare providers and are often the preferred choice for antiemetic prophylaxis and treatment.

Thus, the effectiveness, safety profile, and established market presence shown by the serotonin receptor antagonists increase the demand for antiemetics drugs across the globe during the forecasted period from 2024 to 2030.

North America Is Expected To Dominate The Overall Antiemetics Drugs Market:

North America is expected to account for the highest proportion of the antiemetics drugs market in 2023, out of all regions. This is due to the significant burden of cancer, with a high incidence rate across various types of malignancies in the region. Additionally, the presence of key players in North America like Pfizer Inc., GSK plc, and many others is likely to contribute a higher revenue share of the region.

According to the American Cancer Society's Cancer Facts and Figures 2024 report, approximately 2 million new cancer cases are expected to be diagnosed in 2024 in the United States alone. Among these, prostate cancer is estimated at 299,010 cases, followed by lung cancer at 234,580 cases, and female breast cancer at 310,720 cases, demonstrating a rapid increase in the incidence of cancer cases in the country.

In addition, the growing approvals for antiemetics drugs in the region are anticipated to propel regional expansion. For instance, according to the article published by the Canadian Institutes of Health Research in May 2022, Ondansetron, a 5-HT3 antagonist approved in Canada as an antiemetic, is used for the prevention of postoperative and chemotherapy-related nausea and vomiting. According to the same source, Ondansetron is also used off-label to treat nausea and vomiting during pregnancy and hyperemesis gravidarum, and in the perioperative period during cesarean section. These are some of the key factors driving the growth of the Antiemetics Drugs market in North America.

Thus, the rising incidence of cancer in North America along with the various approval activities taking place will eventually drive the overall market for Antiemetics Drugs in North America during the forecast period.

Antiemetics Drugs Market Key Players:

Some of the key market players operating in the Antiemetics Drugs market include Pfizer Inc., GSK plc, Astellas Pharma Inc., Cipla, Merck & Co., Inc., Eagle Pharmaceuticals, Inc., GLENMARK PHARMACEUTICALS LTD., Viatris Inc., Baxter, Hikma Pharmaceuticals PLC, Novartis AG, Torrent Pharmaceuticals Ltd., Sanofi, Dr. Reddy’s Laboratories Ltd., Lilly, AstraZeneca, F. Hoffmann-La Roche Ltd, Johnson & Johnson Services Inc., Acacia Pharma Group Plc, Boehringer Ingelheim International GmbH.

Recent Developmental Activities In The Antiemetics Drugs Market:

In January 2023, Glenmark Pharmaceuticals Ltd launched AKYNZEO I.V., a unique I.V. injection formulation in India. The medication is useful to prevent chemotherapy-induced vomiting and nausea.

In October 2023, Astellas Pharma Inc. showcased research results at the European Society for Medical Oncology (ESMO) Congress 2023, including an abstract examining the impacts of antiemetic drugs on gastric ulceration and the frequency of vomiting in ferrets.

Key Takeaways From The Antiemetics Drugs Market Report Study

Market size analysis for current Antiemetics Drugs Market size (2023), and market forecast for 6 years (2024 to 2030)

Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years

Key companies dominating the global Antiemetics Drugs market.

Various opportunities are available for the other competitors in the Antiemetics Drugs Market space.

What are the top-performing segments in 2023? How these segments will perform in 2030?

Which are the top-performing regions and countries in the current Antiemetics Drugs market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for Antiemetics Drugs market growth in the coming future?

Target Audience Who Can Be Benefited From This Antiemetics Drugs Market Report Study

Antiemetics Drugs product providers

Research organizations and consulting companies

Antiemetics Drugs -related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in Antiemetics Drugs

Various Distribution Channels who want to know more about the Antiemetics Drugs Market and the latest technological developments in the Antiemetics Drugs Market.

Frequently Asked Questions For The Antiemetics Drugs Market:

1. What are Antiemetics Drugs?

Antiemetic drugs are medications specifically designed to prevent or alleviate nausea and vomiting. Antiemetic drugs are used to manage a wide range of conditions that cause nausea and vomiting, including chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, motion sickness, morning sickness during pregnancy, and gastrointestinal disorders.

2. What is the market for Antiemetics Drugs?

The global antiemetics drugs market is estimated to grow at a CAGR of 6.31% during the forecast period from 2024 to 2030.

3. What are the drivers for the global Antiemetics Drugs market?

The demand for antiemetic drugs, which are medications used to prevent or alleviate nausea and vomiting, is on the rise due to several factors. One significant reason is the increasing prevalence of conditions and treatments that induce nausea and vomiting, such as chemotherapy, radiation therapy, gastroenteritis, gastroparesis, irritable bowel syndrome, and certain surgical procedures. Additionally, there is a growing awareness among healthcare professionals and patients about the importance of managing these symptoms effectively to improve quality of life during illness or recovery. Moreover, with advancements in medical technology and pharmaceutical research, new antiemetic drugs with improved efficacy and fewer side effects are continuously being developed, expanding the options available to patients and healthcare providers. As a result, the demand for antiemetics is expected to continue to increase during the forecast period from 2024 to 2030, as the population ages and as the prevalence of conditions requiring nausea and vomiting management persists.

4. Who are the key players operating in the global Antiemetics Drugs market?

Some of the key market players operating in the Antiemetics Drugs include Pfizer Inc., GSK plc, Astellas Pharma Inc., Cipla, Merck & Co., Inc., Eagle Pharmaceuticals, Inc., GLENMARK PHARMACEUTICALS LTD., Viatris Inc., Baxter, Hikma Pharmaceuticals PLC, Novartis AG, Torrent Pharmaceuticals Ltd., Sanofi, Dr. Reddy’s Laboratories Ltd., Lilly, AstraZeneca, F. Hoffmann-La Roche Ltd, Johnson & Johnson Services Inc., Acacia Pharma Group Plc, Boehringer Ingelheim International GmbH.

5. Which region has the highest share in the global Antiemetics Drugs market?

North America is expected to dominate the overall Antiemetics Drugs market during the forecast period from 2024 to 2030. This is due to the significant burden of cancer, with a high incidence rate across various types of malignancies in the region. Additionally, the presence of key players in North America like Pfizer Inc., GSK plc, and many others are some of the key factors driving the growth of the Antiemetics Drugs market in North America.